Jul. 7 at 3:24 PM
$MCK McKesson has been running lately. With 85-90% institutional ownership and a beta around 0.3, big money clearly sees it as a very stable, defensive play in healthcare. Makes sense with their steady earnings growth in oncology and specialty drugs.